



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Certolizumab pegol

Cat. No.:	HY-P9953
CAS No.:	428863-50-7
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	<p>Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research^{[1][2]}.</p>									
In Vitro	<p>Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC₉₀ of 3 ng/mL^[2]. Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes^[2]. Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC)^[2]. Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)^[3]</td> </tr> <tr> <td>Dosage:</td> <td>10 μg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal administration, single dose</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.</td> </tr> </table>		Animal Model:	Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μ g/kg Cerulein (HY-A0190) (20 μ g/kg, 4 times at 1-hour intervals) ^[3]	Dosage:	10 μ g	Administration:	Intraperitoneal administration, single dose	Result:	Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF- α , and caspase-3 activities.
Animal Model:	Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μ g/kg Cerulein (HY-A0190) (20 μ g/kg, 4 times at 1-hour intervals) ^[3]									
Dosage:	10 μ g									
Administration:	Intraperitoneal administration, single dose									
Result:	Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF- α , and caspase-3 activities.									

REFERENCES

[1]. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. *Drugs*. 2013 Jan;73(1):75-97.

[2]. Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. *Inflamm Bowel Dis.* 2007 Nov;13(11):1323-32.

[3]. Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. *Pancreas.* 2016 Sep;45(8):1120-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA